Kimberly-Clark completes its acquisition of Kenvue
Kimberly-Clark completed its acquisition of Kenvue, combining consumer health and personal care portfolios and bringing the combined company to 10 billion-dollar brands. The company expects about $2.1 billion in annual run-rate synergies, including $1.9 billion in cost savings within three years. Kenvue shareholders receive $3.50 cash and 0.14625 Kimberly-Clark shares per share.
Jim Cramer’s Charitable Trust adds Kimberly-Clark shares
Kimberly-Clark had paid dividends for 92 consecutive years and raised its quarterly payout for the 54th straight year in January, to $1.28 per share. The November 2 completion of its Kenvue acquisition added uncertainty: in the nine months through September, cash flow exceeded capital spending and dividends by only $101 million.
Kimberly-Clark faces weak sales and Kenvue integration challenges
Kimberly-Clark’s shares fell 16.5% over five years, underperforming the S&P 500. Although 2025 comparable sales rose 1.7% on higher volume, reported sales declined 2.9% due to divestitures and currency effects. Competitive pressure led to price cuts, and third-quarter adjusted sales fell 1.3%, with gross margin down 1.3 percentage points.
Kimberly-Clark’s dividend has risen for 55 straight years
At a share price of $108.43 and annual dividend of $5.12, a $10,000 investment would buy 92 shares and generate about $471 in annual dividends. The article described the payout as reasonably safe, though further increases were not guaranteed. Kimberly-Clark had finalized its nearly $49 billion Kenvue acquisition and expected $1.9 billion in cost efficiencies over three years.
Kimberly-Clark’s Kenvue deal raises questions about dividend coverage
Kimberly-Clark had raised its dividend for 54 consecutive years, but 2025 dividend payments of $1.66 billion slightly exceeded free cash flow of $1.64 billion. The Kenvue acquisition was expected to dilute adjusted EPS by mid-single digits in its first full year. Management targeted roughly $1.9 billion in cost synergies and leverage near two times by the end of year two.
Kimberly-Clark targets $1.9 billion in Kenvue cost synergies
Management outlined a phased integration plan focused on operational continuity, cost synergies, brand investment and growth. Kimberly-Clark expects 2027 adjusted EPS to be diluted by up to the mid-single digits, followed by mid- to high-single-digit growth through 2028. It maintained its standalone 2026 outlook while citing China disruption, North American pressures and roughly $250 million in expected full-year inflation.
Kimberly-Clark posts $1.70 in adjusted third-quarter earnings
Kimberly-Clark reported third-quarter revenue of $4.13 billion, down 0.4% year over year, and adjusted EPS of $1.70, above estimates. Organic sales fell 1.3%, with China disruption and North American retail inventory movements weighing on results. North American sales rose modestly, while International Personal Care sales weakened. The company reaffirmed its standalone 2026 outlook.
Kimberly-Clark’s dividend record draws attention after Kenvue deal
Kimberly-Clark had raised its dividend for 54 consecutive years and paid dividends for 92 years, supported by steady profits and demand for household essentials. The company reported 2025 sales of $16.4 billion, down 2.1% year over year, and completed its acquisition of Kenvue, adding brands including Tylenol and Band-Aid while introducing integration risks. Its dividend yield was 4.7%.
Zacks cited stagnant long-term sales, nearly flat organic growth in the second quarter, weaker China sales and a lowered 2026 outlook. Analysts had cut current- and next-year earnings estimates by about 8%, and the Kenvue acquisition was described as adding debt and integration risks. The coverage assigned Kimberly-Clark a Zacks Rank #5 (Strong Sell).
Kimberly-Clark reports final results of Kenvue note exchanges
The offers expired November 2, and settlement was expected November 4, 2026. Kimberly-Clark will exchange accepted notes for its own senior unsecured notes and, for early tenders, a cash payment. The new notes retain the corresponding Kenvue notes’ interest rates and maturities; consent amendments to the Kenvue indenture become operative upon settlement.
Analysts expect Kimberly-Clark’s third-quarter earnings to decline
Analysts expected Kimberly-Clark’s third-quarter earnings to fall 8.8% year over year to $1.66 per share, with revenue down 0.1% to $4.15 billion. Estimates cited cautious consumer spending, competition, China diaper-business disruptions and elevated input and brand-investment costs, partly offset by product innovation, international demand and efficiency savings.